Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$25.06 USD
+0.32 (1.29%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $25.01 -0.05 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Nurix Therapeutics, Inc falls in the month of November .
All items in Millions except EPS data.
11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 | |
---|---|---|---|---|---|
Sales | 77 | 39 | 30 | 18 | 31 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 77 | 39 | 30 | 18 | 31 |
Selling & Adminstrative & Depr. & Amort Expenses | 232 | 223 | 148 | 83 | 53 |
Income After Depreciation & Amortization | -155 | -184 | -118 | -65 | -22 |
Non-Operating Income | 11 | 4 | 1 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -144 | -180 | -117 | -64 | -21 |
Income Taxes | 0 | 0 | 0 | -21 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -144 | -180 | -117 | -43 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -144 | -180 | -117 | -43 | -22 |
Depreciation Footnote | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -147 | -173 | -110 | -63 | -20 |
Depreciation & Amortization (Cash Flow) | 8 | 11 | 8 | 2 | 2 |
Income After Depreciation & Amortization | -155 | -184 | -118 | -65 | -22 |
Earnings Per Share Data | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Average Shares | 54.34 | 48.61 | 42.90 | 15.67 | NA |
Diluted EPS Before Non-Recurring Items | -2.65 | -3.71 | -2.73 | -2.76 | NA |
Diluted Net EPS (GAAP) | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
Fiscal Year end for Nurix Therapeutics, Inc falls in the month of November .
All items in Millions except EPS data.
8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | |
---|---|---|---|---|---|
Sales | NA | 12.09 | 16.59 | 15.16 | 18.47 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 12.09 | 16.59 | 15.16 | 18.47 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 60.63 | 61.81 | 60.49 | 58.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -48.54 | -45.22 | -45.33 | -40.01 |
Non-Operating Income | NA | 4.08 | 3.79 | 3.38 | 3.03 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -44.46 | -41.43 | -41.96 | -36.98 |
Income Taxes | NA | 0.09 | 0.09 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -44.55 | -41.52 | -41.96 | -36.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -44.55 | -41.52 | -41.96 | -36.98 |
Earnings Per Share Data | 8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 62.38 | 54.90 | 54.67 | 54.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.71 | -0.76 | -0.77 | -0.68 |
Diluted Net EPS (GAAP) | NA | -0.71 | -0.76 | -0.77 | -0.68 |